Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3402/jchimp.v5.27297 http://scihub22266oqcxt.onion/10.3402/jchimp.v5.27297 C4475268!4475268!26091655     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Community+Hosp+Intern+Med+Perspect 2015 ; 5 (3): ä Nephropedia Template TP {{tp|p=26091655|t=2015. Evaluation of N-acetylcysteine for the prevention of contrast-induced nephropathy |pdf=|usr=}}{{26091655}} gab.com Text Evaluation of N-acetylcysteine for the prevention of contrast-induced nephropathy JO: J Community Hosp Intern Med Perspect http://www.kidney.de/pget.php?&tw=1&pmid=26091655 #FOAvip Background: Contrast-induced nephropathy (CIN) remains a leading cause of acute renal failure in hospitalized patients. N-Acetylcysteine has been studied previously for the prevention of CIN, resulting in mixed findings. Objective: The objective of this study was to determine the impact of N-acetylcysteine on the development of CIN in order to guide its use at community, teaching hospitals. Methods: Patients admitted between January 1 and December 31, 2011, receiving intravenous radiocontrast dye were included if they were compliant with two or more of the following conditions: baseline serum creatinine >1.2 mg/dL or estimated creatinine clearance <50 mL/min, age ?75 years, diabetes mellitus, heart failure, or hypertension. The primary outcome was the difference in the proportion of patients in each group (N-acetylcysteine or no N-acetylcysteine) who developed CIN, which was defined as a ?0.5 mg/dL increase in serum creatinine or a ?25% increase in serum creatinine within 12?96 hours post-exposure to contrast. Results: A total of 302 patients were included, 151 who received N-acetylcysteine and 151 who did not receive N-acetylcysteine. Patients who received N-acetylcysteine had significantly worse renal function at baseline than those who did not receive N-acetylcysteine (mean pre-contrast serum creatinine, 1.41 vs. 0.95 mg/dL, p<0.0001). A lower proportion of patients developing CIN was observed between those who received N-acetylcysteine and those who did not receive N-acetylcysteine (10.2% vs. 21.8%, p=0.0428). Conclusions: The use of N-acetylcysteine was likely associated with a reduced incidence of CIN in patients at risk for CIN development. Based on these results, hospitals may benefit from the development of a protocol to guide the appropriate use of N-acetylcysteine. Twit Text FOAVip Evaluation of N-acetylcysteine for the prevention of contrast-induced nephropathy ????J Community Hosp Intern Med Perspect http://www.kidney.de/pget.php?&tw=1&pmid=26091655 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26091655 #FOAvip English Wikipedia <ref>{{Cite pmid|26091655}}</ref> Evaluation of N-acetylcysteine for the prevention of contrast-induced nephropathy #MMPMID26091655 Richter SK; Crannage AJ J Community Hosp Intern Med Perspect 2015[]; 5 (3): ä PMID26091655show ga Background: Contrast-induced nephropathy (CIN) remains a leading cause of acute renal failure in hospitalized patients. N-Acetylcysteine has been studied previously for the prevention of CIN, resulting in mixed findings. Objective: The objective of this study was to determine the impact of N-acetylcysteine on the development of CIN in order to guide its use at community, teaching hospitals. Methods: Patients admitted between January 1 and December 31, 2011, receiving intravenous radiocontrast dye were included if they were compliant with two or more of the following conditions: baseline serum creatinine >1.2 mg/dL or estimated creatinine clearance <50 mL/min, age ?75 years, diabetes mellitus, heart failure, or hypertension. The primary outcome was the difference in the proportion of patients in each group (N-acetylcysteine or no N-acetylcysteine) who developed CIN, which was defined as a ?0.5 mg/dL increase in serum creatinine or a ?25% increase in serum creatinine within 12?96 hours post-exposure to contrast. Results: A total of 302 patients were included, 151 who received N-acetylcysteine and 151 who did not receive N-acetylcysteine. Patients who received N-acetylcysteine had significantly worse renal function at baseline than those who did not receive N-acetylcysteine (mean pre-contrast serum creatinine, 1.41 vs. 0.95 mg/dL, p<0.0001). A lower proportion of patients developing CIN was observed between those who received N-acetylcysteine and those who did not receive N-acetylcysteine (10.2% vs. 21.8%, p=0.0428). Conclusions: The use of N-acetylcysteine was likely associated with a reduced incidence of CIN in patients at risk for CIN development. Based on these results, hospitals may benefit from the development of a protocol to guide the appropriate use of N-acetylcysteine. äEvaluation of N-acetylcysteine for the prevention of contrast-induced (epmc).pdf DeepDyve Pubget Overpricing